Comparing Ready‐to‐Use and Powder AbobotulinumtoxinA for Glabellar Lines: A Randomized, Controlled, Triple‐Blinded Clinical Trial
Journal of Cosmetic Dermatology · 2025
DOI: 10.1111/jocd.70308 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Silvio Ventura da Silva Junior und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dentistry, Ingá University Center, Uningá, Maringá, Paraná, Brazil. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Skin Aging, Neuromuscular Agents, Cosmetic Techniques. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Next Gen/Santader Post Doc.
Abstract (Originalsprache)
Background
Botulinum toxin A (BoNT‐A) is the most used procedure to treat glabellar lines; however, limited data exist about the effectiveness of ready‐to‐use BoNT‐A (RTUaboBoNT‐A) for this indication.
Aims
This study compared the efficacy, durability, and safety of RTUaboBoNT‐A for moderate and severe glabellar wrinkles.
Methods
This randomized triple‐blinded trial included 38 male volunteers aged between 25 and 50 years. Participants were randomly divided into two groups: abobotulinumtoxinA (aboBoNT‐A, n = 18) and RTUaboBoNT‐A ( n = 20). Groups received 10 U for procerus muscle and 20 U for the corrugator muscle. Assessed variables included, electromyography activity (EMG), Merz 5‐point glabellar lines scale, FACE‐Q appraisal for lines between the eyebrows and Visual Analogue Scale for pain intensity. Assessments were performed before and 1, 2, 3, and 4 months after injections. For differences in EMG and satisfaction scores, the two‐way repeated‐measures ANOVA and Bonferroni's post hoc analyses were conducted. Wrinkle severity scores were analyzed with the chi‐squared test.
Results
Inter‐group comparisons revealed no significant differences in EMG scores in all assessed periods for the corrugator supercili ( p = 0.11) and the procerus muscles ( p = 0.93); for severity of glabellar lines, no significant differences were also found in all follow‐ups for rest ( p = 0.737) and contracted position ( p = 0.390), as well as for satisfaction with the treatments. However, the RTUaboBoNT‐A group presented higher levels of pain intensity during the injection procedure ( p = 0.01).
Conclusion
The RTUaboBoNT‐A and aboBoNT‐A are comparable in efficacy, durability, and safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dentistry, Ingá University Center, Uningá, Maringá, Paraná, Brazil.
- Department of Dentistry, University of Ponta Grossa, Ponta Grossa, Paraná, Brazil.
- Egas Moniz Center for Interdisciplinary Research (CiiEM), Egas Moniz School of Health & Science, Caparica, Almada, Portugal.
- Orofacial Pain Unit, CUF Tejo Hospital, Lisboa, Portugal.
- Department of Dentistry, State University of Maringá, Maringá, Paraná, Brazil.
- Orofacial Institute of the Americas - IOA Maringá, Maringá, Paraná, Brazil.
ORCID-Profile: Giancarlo De la Torre Canales
Förderung
- Next Gen/Santader Post Doc
Zitieren
APA
da Silva Junior, S. V., Borges Neves, M. L. B., Sanchez-Ayala, A., Cebola, P. M. T. C., Carbone, A. C., Câmara-Souza, M. B., Poluha, R. L., & De la Torre Canales, G. (2025). Comparing Ready‐to‐Use and Powder AbobotulinumtoxinA for Glabellar Lines: A Randomized, Controlled, Triple‐Blinded Clinical Trial. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.70308
Vancouver
da Silva Junior SV, Borges Neves MLB, Sanchez-Ayala A, Cebola PMTC, Carbone AC, Câmara-Souza MB, et al. Comparing Ready‐to‐Use and Powder AbobotulinumtoxinA for Glabellar Lines: A Randomized, Controlled, Triple‐Blinded Clinical Trial. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.70308
BibTeX
@article{daSilvaJunior2025,
author = {da Silva Junior, Silvio Ventura and Borges Neves, Maria Luiza Boechat and Sanchez-Ayala, Alfonso and Cebola, Pedro Miguel Teixeira Carvas and Carbone, Ana Claudia and Câmara-Souza, Mariana Barbosa and Poluha, Rodrigo Lorenzi and De la Torre Canales, Giancarlo},
title = {Comparing Ready‐to‐Use and Powder AbobotulinumtoxinA for Glabellar Lines: A Randomized, Controlled, Triple‐Blinded Clinical Trial},
journal = {Journal of Cosmetic Dermatology},
year = {2025},
doi = {10.1111/jocd.70308}
}
EUVIMED